SEC Form 4 · accession 0001951287-26-000004
ARS Pharmaceuticals, Inc. · SPRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Karas
Officer — Chief Commercial Officer
Period of report
Jun 12, 2026
Accepted (ET)
Jun 12, 2026 · 8:06 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001671858
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 12, 2026 | M | 25,000 | $1.50 | A | 37,176 | D | |
| Common Stock | Jun 12, 2026 | S | 25,000 | $10.00 | D | 12,176 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $1.50 | Jun 12, 2026 | M | 25,000 | D | — | May 23, 2032 | Common Stock | 25,000 | 519,588 | D |
Explanation of responses
- F1Includes 1,861 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2025.
- F2The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.
- F3Immediately exercisable.